NantKwest (NK) Receives Price Target

NantKwest (NK) : 4 Wall Street analysts covering NantKwest (NK) believe that the average level the stock could reach for the short term is $30. The maximum price target given is $38 and the minimum target for short term is around $23, hence the standard deviation is calculated at $6.16.

NantKwest (NK) : 4 brokerage houses believe that NantKwest (NK) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on NantKwest (NK). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 5 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.4.


Also, Raymond James initiates coverage on NantKwest (NASDAQ:NK) . Analysts at the Raymond James have a current rating of Market Perform on the shares. The rating by the firm was issued on June 2, 2016.

NantKwest (NASDAQ:NK): The stock opened at $8.13 on Thursday but the bulls could not build on the opening and the stock topped out at $8.19 for the day. The stock traded down to $7.81 during the day, due to lack of any buying support eventually closed down at $8.04 with a loss of -0.62% for the day. The stock had closed at $8.09 on the previous day. The total traded volume was 175,182 shares.

NantKwest, Inc., formerly Conkwest, Inc., is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. The Companys product candidates include aNK, haNK and taNK. The Companys aNK product candidates are unmodified aNK cells with natural affinity to stress-induced ligands of diseased cells. The Company develops its aNK product candidates as monotherapies for the treatment of virally-induced cancers, such as polyomavirus induced Merkel cell carcinoma, human Papillomavirus (HPV), induced cervical cancer and head and neck cancer. Its haNK product candidates are aNK cells genetically engineered to express high-affinity CD16, a receptor that allows direct binding of NK cells to antibodies. The Companys taNK product candidate targets specific antigens on the surface of abnormal cells, including CD33, EGFR, HER2/neu, PDL1 and PSMA.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.